Abstract
BackgroundStandard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination with standard therapies in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have